Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20291545 | 0.85 | KDM4E (0.45) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL439056 | 0.85 | BCHE (0.56) | CYP2D6PTGS2BCHEHTR1AADRB3 | |
| SCHEMBL179726 | 0.85 | P2RX4 (0.56) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL18258640 | 0.78 | KMT2A (0.61) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL281623 | 0.78 | KMT2A (0.61) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL18974288 | 0.78 | KMT2A (0.61) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL125972 | 0.77 | LMNA (0.71) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL7399848 | 0.77 | LMNA (0.71) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL478339 | 0.77 | LMNA (0.71) | KMT2AKDM4EGAACASP1CASP7 | |
| SCHEMBL29472125 | 0.77 | LMNA (0.71) | KMT2AKDM4EGAACASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519504-B2 | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | BERG LLC (US) | 2019-12-31 | — | — | US | disclosed |
| US-9205064-B2 | Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | BERG LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150023940-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG PHARMA LLC (US) | 2015-01-22 | — | — | US | disclosed |
| US-8580442-B2 | Fuel cell system and method of repairing electrolyte membrane thereof | NISSAN MOTOR CO., LTD. (JP) | 2013-11-12 | — | — | US | disclosed |
| EP-1942541-B1 | FUEL CELL SYSTEM AND METHOD FOR REPAIRING ELECTROLYTE FILM THEREOF | NISSAN MOTOR (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110123986-A1 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG PHARMA LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110123987-A1 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BPGBIO, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110110914-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG, KARA ANN | 2011-05-12 | — | — | US | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| US-20090226773-A1 | FUEL CELL SYSTEM AND METHOD OF REPAIRING ELECTROLYTE MEMBRANE THEREOF | NISSAN MOTOR CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1942541-A1 | FUEL CELL SYSTEM AND METHOD FOR REPAIRING ELECTROLYTE FILM THEREOF | Nissan Motor Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110914-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | SHMT2, IDH2, GSR | KMT2A 1977/4885KDM4E 2809/4885GAA 881/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | KMT2A 2829/4885KDM4E 2944/4885GAA 300/4885 |
| US-20150023940-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | KMT2A 1796/4885KDM4E 2057/4885GAA 863/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | KMT2A 1796/4885KDM4E 2057/4885GAA 863/4885 |
| US-10519504-B2 | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | SHMT2, IDH2, GSR | KMT2A 1977/4885KDM4E 2809/4885GAA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.